ConductScience.org, home

Comparison · NCT02980276-338fa665

Treatment vs Control: Maternal Morbidity - Antepartum Hemorrhage

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Treatment vs Control: Maternal Morbidity - Antepartum Hemorrhage. Trial comparisons, record NCT02980276-338fa665. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02980276-338fa665

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.05730.0350.0923wilson
Risk in group 20.1030.07180.146wilson
Risk difference, group 1 minus group 2-0.0458-0.0940.00116newcombe hybrid score
Risk ratio, group 1 over group 20.5560.3031.02log
Odds ratio, group 1 over group 20.5290.2741.02log
Number needed to treat, for one fewer participant with the outcome on Treatment than on Control21.8from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: control.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Treatment
Participants randomised to the treatment arm received active metformin in addition to standard care. Metformin tablets will be titrated according to a dosing schedule to achieve the pre-specified glucose targets. Tablets will be in 500mg doses and will commence at 1 tablet per day (500mg) increasing to a maximum of 5 tablets per day (2500mg).
15262OG000
Group 2Control
Participants randomised to the placebo arm received placebo in addition to standard care. Placebo will be titrated according to the dosing schedule to achieve the pre-specified glucose targets. Placebo tablets will commence at 1 tablet per day and will be increased to a maximum of 5 tablets per day over 10 days as with the treatment group.
27262OG001

Outcome

Type
SECONDARY
Title
Maternal Morbidity - Antepartum Hemorrhage
Description
Any vaginal bleeding prior to delivery
Time frame
From enrolment through delivery, an average of 16 weeks.
Population

Source ClinicalTrials.gov

Trial

Title
RCT Metformin for Reduction of Gestational Diabetes Mellitus Effects
NCT number
NCT02980276
Phases
PHASE3
Conditions
Gestational Diabetes
Interventions
Metformin Hydrochloride, Placebo
Lead sponsor
National University of Ireland, Galway, Ireland
Results first posted
2025-03-17

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02980276-338fa665